Vontobel Holding Ltd. Has $479,000 Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)

Vontobel Holding Ltd. lessened its stake in Vir Biotechnology, Inc. (NASDAQ:VIR) by 6.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,599 shares of the company’s stock after selling 3,220 shares during the quarter. Vontobel Holding Ltd.’s holdings in Vir Biotechnology were worth $479,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in VIR. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Vir Biotechnology by 96.4% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,448 shares of the company’s stock valued at $32,000 after buying an additional 1,692 shares during the period. Fifth Third Bancorp boosted its holdings in Vir Biotechnology by 69.3% during the third quarter. Fifth Third Bancorp now owns 3,941 shares of the company’s stock worth $37,000 after purchasing an additional 1,613 shares during the last quarter. CWM LLC boosted its holdings in Vir Biotechnology by 882.7% during the third quarter. CWM LLC now owns 7,488 shares of the company’s stock worth $70,000 after purchasing an additional 6,726 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Vir Biotechnology by 99.9% during the third quarter. PNC Financial Services Group Inc. now owns 9,317 shares of the company’s stock worth $87,000 after purchasing an additional 4,656 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC acquired a new position in Vir Biotechnology during the third quarter worth $99,000. Institutional investors and hedge funds own 65.32% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on VIR. HC Wainwright restated a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a report on Friday, March 15th. JPMorgan Chase & Co. increased their target price on shares of Vir Biotechnology from $9.00 to $10.00 and gave the stock a “neutral” rating in a report on Friday, February 23rd. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $34.38.

Vir Biotechnology Trading Up 1.9 %

NASDAQ VIR opened at $8.10 on Tuesday. The firm’s fifty day moving average price is $10.08 and its two-hundred day moving average price is $9.62. Vir Biotechnology, Inc. has a 1 year low of $7.72 and a 1 year high of $27.48. The firm has a market capitalization of $1.09 billion, a P/E ratio of -1.76 and a beta of 0.41.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Thursday, February 22nd. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.28. Vir Biotechnology had a negative net margin of 713.69% and a negative return on equity of 34.92%. The firm had revenue of $16.80 million for the quarter, compared to analyst estimates of $11.18 million. During the same period in the prior year, the firm posted ($0.76) earnings per share. The company’s quarterly revenue was down 66.0% compared to the same quarter last year. On average, research analysts anticipate that Vir Biotechnology, Inc. will post -4.04 EPS for the current fiscal year.

Insider Activity

In other news, CEO Backer Marianne De sold 72,995 shares of the stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $9.46, for a total value of $690,532.70. Following the transaction, the chief executive officer now directly owns 678,457 shares of the company’s stock, valued at $6,418,203.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, EVP Ann M. Hanly sold 2,711 shares of the stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $10.05, for a total value of $27,245.55. Following the transaction, the executive vice president now directly owns 132,069 shares of the company’s stock, valued at $1,327,293.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Backer Marianne De sold 72,995 shares of the stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $9.46, for a total transaction of $690,532.70. Following the completion of the transaction, the chief executive officer now directly owns 678,457 shares in the company, valued at $6,418,203.22. The disclosure for this sale can be found here. Insiders have sold 152,831 shares of company stock valued at $1,525,844 over the last ninety days. 18.10% of the stock is currently owned by company insiders.

Vir Biotechnology Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.